Subtyping strokes using blood‐based protein biomarkers: A high‐throughput proteomics and machine learning approach
- 10 December 2024
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 55 (4) , e14372
Abstract
Background: Rapid diagnosis of stroke and its subtypes is critical in early stages. We aimed to discover and validate blood‐based protein biomarkers to differentiate ischemic stroke (IS) from intracerebral haemorrhage (ICH) using high‐throughput proteomics.Methods: We collected serum samples within 24 h from acute stroke (IS & ICH) and mimics patients. In the discovery phase, SWATH‐MS proteomics identified differentially expressed proteins, which were validated using targeted proteomics in the validation phase. We conducted interaction network and pathway analyses using Cytoscape 3.10.0. We determined cut‐off points using the Youden Index. We developed three prediction models using multivariable logistic regression analyses. We assessed the model performance using statistical tests.Results: We included 20 IS and 20 ICH in the discovery phase and 150 IS, 150 ICH, and six stroke mimics in the validation phase. We quantified 375 proteins using SWATH‐MS. Between IS and ICH, we discovered 20 differentially expressed proteins. In the validation phase, the combined prediction model including three biomarkers: GFAP (aOR 0.04; 95%CI .02–.11), MMP‐9 (aOR .09; .03–.28), APO‐C1 (aOR 5.76; 2.66–12.47) and clinical variables independently differentiated IS from ICH (accuracy: 92%, negative predictive value: 94%). Adding biomarkers to clinical variables improved discrimination by 26% (p < .001). Additionally, nine biomarkers differentiated IS from ICH within 6 h, while three biomarkers differentiated IS from mimics.Conclusions: Our study demonstrated that GFAP, MMP‐9 and APO‐C1 biomarkers independently differentiated IS from ICH within 24 h and significantly improved the discrimination ability of prediction models. Temporal profiling of these biomarkers in the acute phase of stroke is warranted.Keywords
Funding Information
- All-India Institute of Medical Sciences (8‐762/A‐762/2019/RS)
This publication has 34 references indexed in Scilit:
- The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trialThe Lancet, 2023
- Association between matrix metalloproteinase family gene polymorphisms and risk of ischemic stroke: A systematic review and meta-analysis of 29 studiesGene, 2018
- Blood‐based protein biomarkers for stroke differentiation: A systematic reviewProteomics – Clinical Applications, 2017
- Apolipoprotein A-I and Paraoxonase-1 Are Potential Blood Biomarkers for Ischemic Stroke DiagnosisJournal of Stroke and Cerebrovascular Diseases, 2016
- The use of serum glial fibrillary acidic protein test as a promising tool for intracerebral hemorrhage diagnosis in Chinese patients and prediction of the short-term functional outcomesNeurological Sciences, 2015
- Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsThe Lancet, 2014
- Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathwayJournal of Proteomics, 2012
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Astroglial Proteins as Diagnostic Markers of Acute Intracerebral Hemorrhage—Pathophysiological Background and Clinical FindingsTranslational Stroke Research, 2010
- ApoC‐I and ApoC‐III as potential plasmatic markers to distinguish between ischemic and hemorrhagic strokeProteomics, 2004